TotalMarketCap

Inhibrx Biosciences

INBXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.374 B

$93.36 -0.05%

Close of 8 Oct 2026

As of 8 Oct 2026, Inhibrx Biosciences (INBX) has a market capitalization of $1.37B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$1.30M

#3455 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

14,717,660

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →
  1. #39Maze TherapeuticsMAZE$1.46B
  2. #40Taysha Gene TherapiesTSHA$1.44B
  3. #41Inhibrx BiosciencesINBX$1.37B
  4. #42Hemab TherapeuticsCOAG$1.34B
  5. #43Replimune GroupREPL$1.24B

What if Inhibrx Biosciences were worth as much as…

Open the what-if tool →

Gold $29.0T

$1,970,082

Per share 21,102× higher

Bitcoin $1.65T

$111,908.39

Per share 1,199× higher

Nvidia $5.72T

$388,854.41

Per share 4,165× higher

Or at a round number

$2.00B$5.00B$10.0B$20.0B

Where these numbers come from

Share counts and financials for Inhibrx Biosciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Oct 2026. Read the methodology.